Doripenem is a carbapenem antibiotic that is used to treat serious bacterial infections. It is a synthetic compound with a broad spectrum of activity against gram-positive and gram-negative bacteria. Doripenem inhibits bacterial cell wall synthesis, leading to bacterial cell lysis. Doripenem is studied because it is effective against a wide range of bacteria, including those that are resistant to other antibiotics. Doripenem has been shown to be effective in the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and pneumonia. It is also being studied for its potential use in the treatment of other infections, such as sepsis and meningitis.'
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73303 |
| CHEMBL ID | 491571 |
| CHEBI ID | 135928 |
| SCHEMBL ID | 37471 |
| MeSH ID | M0260551 |
| Synonym |
|---|
| doribax |
| doripenem |
| s-4661 |
| doripenem (usan/inn) |
| D03895 |
| 148016-81-3 |
| NCGC00167510-01 |
| CHEBI:135928 |
| (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3s,5s)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| CHEMBL491571 |
| dtxsid2046678 , |
| cas-148016-81-3 |
| tox21_112508 |
| dtxcid0026678 |
| BCP9000623 |
| AKOS015918362 |
| doripenem [usan:inn] |
| 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- |
| (+)-(4r,5s,6s)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3s,5s)-5-((sulfamoylamino)methyl)-3-pyrrolidinyl)thio)-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid |
| 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, (4r,5s,6s)- |
| bhv525jobh , |
| unii-bhv525jobh |
| BCPP000252 |
| doripenem [ema epar] |
| doripenem [mart.] |
| doripenem [vandf] |
| doripenem [mi] |
| doripenem [orange book] |
| doripenem [inn] |
| doripenem [who-dd] |
| doripenem [usan] |
| AM84446 |
| S5531 |
| CS-2075 |
| HY-B0187 |
| SCHEMBL37471 |
| NCGC00167510-02 |
| tox21_112508_1 |
| (4r,5s,6s)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3s,5s)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| bdbm50088382 |
| DB06211 |
| (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-{[(3s,5s)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| sr-01000872589 |
| SR-01000872589-1 |
| mfcd02092739 |
| Q411552 |
| AVAACINZEOAHHE-VFZPANTDSA-N |
| D5249 |
| (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-({(3s,5s)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl}sulfanyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| O6P , |
| CCG-268891 |
| (4r,5s,6s)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3s,5s)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid |
| (4r,5s,6s)-3-[[(3s,5s)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| EN300-18166989 |
| gtpl12183 |
| compound 1m [pmid: 8621362] |
| j01dh04 |
| doripenem (mart.) |
| doripenemum |
Doripenem is a new carbapenem antimicrobial with activity against a range of gram-negative organisms, including Pseudomonas aeruginosa. There is a lack of studies validating the recommended dosage regimen for patients admitted to intensive care unit (ICU), based on pharmacokinetic (PK)/pharmacodynamic (PD) index. Doripenm is a viable option for treating APAC patients with NP, VAP, cIAI or cUTI.
Doripenem has a relatively low potential to induce seizures. It has a broad spectrum of activity against many common hospital pathogens.
Doripenem has been approved for use in treatment of complicated intra-abdominal infection and complicated urinary tract infection. It is used for severe infections in the intensive care unit. Doripenam has a relatively low potential to induce seizures.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Doripenem has a slightly greater in vitro activity than imipenem in terms of zone breakpoints and MIC values, but its activity is comparable to meropenem." | ( Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii. Abdollahi, A; Aliramezani, A; Boroumand, MA; Douraghi, M; Ghalavand, Z; Ghourchian, S; Mohammadzadeh, M; Nateghi Rostami, M; Rahbar, M; Zeraati, H, 2016) | 1.88 |
| "Doripenem has a relatively low potential to induce seizures." | ( Doripenem: a new carbapenem antibiotic. Chahine, EB; Ferrill, MJ; Poulakos, MN, 2010) | 2.52 |
| "Doripenem has a broad spectrum of activity against many common hospital pathogens, including P." | ( Doripenem. Anderson, DL, 2006) | 2.5 |
| "As doripenem has unique potential for use in prolonged infusions, suggested pharmacodynamic (PD) breakpoints range from 2-8 μg/mL; synergistic activity was found for higher proportions of XDR-GNB at higher PD breakpoints with doripenem with amikacin or with rifampin." | ( In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Alba, L; Clock, SA; Kubin, CJ; Saiman, L; Tabibi, S; Whittier, S, 2013) | 1.22 |
| "Doripenem has been recently introduced in Malaysia and is used for severe infections in the intensive care unit. " | ( Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. Abd Rahman, AN; Abdul-Aziz, MH; Lipman, J; Mat-Nor, MB; Roberts, JA; Staatz, CE; Sulaiman, H; Wallis, SC, 2016) | 2.16 |
| "Doripenem has a slightly greater in vitro activity than imipenem in terms of zone breakpoints and MIC values, but its activity is comparable to meropenem." | ( Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii. Abdollahi, A; Aliramezani, A; Boroumand, MA; Douraghi, M; Ghalavand, Z; Ghourchian, S; Mohammadzadeh, M; Nateghi Rostami, M; Rahbar, M; Zeraati, H, 2016) | 1.88 |
| "Doripenem has been approved for use in treatment of complicated intra-abdominal infection and complicated urinary tract infection." | ( Doripenem. Depestel, DD; Paterson, DL, 2009) | 2.52 |
| "Doripenem has a relatively low potential to induce seizures." | ( Doripenem: a new carbapenem antibiotic. Chahine, EB; Ferrill, MJ; Poulakos, MN, 2010) | 2.52 |
| "Doripenem has also completed two phase I studies in healthy volunteers with a number of different dosing regimens." | ( Doripenem: S 4661. , 2003) | 2.48 |
| "Doripenem has a broad spectrum of activity against many common hospital pathogens, including P." | ( Doripenem. Anderson, DL, 2006) | 2.5 |
Doripenem displays the favourable characteristics of other carbapenems, and appears to offer certain advantages in terms of potency, spectrum and beta-lactamase stability. Doripenm MIC90s were lower than those of all other comparative agents against all isolates combined.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Doripenem displays the favourable characteristics of other carbapenems, and appears to offer certain advantages in terms of potency, spectrum and beta-lactamase stability when compared with some carbapenems used currently to treat nosocomial infections." | ( Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Fritsche, TR; Jones, RN; Stilwell, MG, 2005) | 1.35 |
| "Doripenem MIC90s were lower than those of all other comparative agents against all isolates combined and against all P." | ( In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Brown, SD; Traczewski, MM, 2006) | 1.37 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Doripenem treatment was recorded in 102 patients. " | ( Evaluation of doripenem utilization and susceptibilities at a large urban hospital. Balderson, BJ; Patil, NP; Suda, KJ; Yates, ME, 2011) | 2.17 |
Doripenem was generally found to be safe and well tolerated. The proportion of subjects reporting one or more treatment-emergent adverse events or serious adverse events was similar for doripENem and the comparator agents.
Doripenem (DRPM) is a broad-spectrum antibacterial agent often used as empirical therapy for critically ill patients. There is a lack of studies validating the recommended dosage regimen for patients admitted to intensive care unit (ICU)
The aim of this study was to evaluate the in vitro activity of doripenem (DOR) alone and in combination with a variety of commonly used anti-Acinetobacter chemotherapeutic agents. Colistin, tigecycline, levofloxacin, tobramycin, and rifampin were investigated for their in vitro activities and postantibiotic effects.
| Excerpt | Reference | Relevance |
|---|---|---|
| "ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillin-tazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes." | ( Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa. Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA, 2011) | 0.61 |
| "The aim of this study was to evaluate the in vitro activity of doripenem (DOR) alone and in combination with a variety of commonly used anti-Acinetobacter chemotherapeutic agents against 22 primary multidrug-resistant (MDR) Acinetobacter baumannii isolates (including 17 isolates that were resistant to DOR) from Intensive Care Unit patients." | ( In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L, 2013) | 0.95 |
| "Colistin, tigecycline, levofloxacin, tobramycin, and rifampin alone and in combination with doripenem were investigated for their in vitro activities and postantibiotic effects (PAEs) on Klebsiella pneumoniae." | ( Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit. Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M, 2014) | 0.86 |
| " Imipenem, meropenem and doripenem were significantly more effective (reduced fold-change of MICs) when combined with rifampicin in bla VIM-negative isolates, especially in isolates with porin frameshift mutation." | ( In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Hu, YF; Liu, CP; Shih, SC; Wang, NY, 2016) | 0.96 |
| " In this study, the activity of colistin (COL) as monotherapy and in combination with other antibiotics against Acinetobacter baumannii in vitro was investigated." | ( In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli. Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z, 2020) | 0.56 |
| " The in-vitro bactericidal and synergistic activities of ceftazidime/avibactam alone or in combination with other antibiotics were determined by time-kill curve assays." | ( Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Istanbullu Tosun, A; Mataraci Kara, E; Özbek Çelik, B; Yilmaz, M, 2020) | 0.78 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Doripenem and ciprofloxacin were compared to restrict the enrichment of resistant Pseudomonas aeruginosa. Simulating two dosing scenarios gave doripENem levels in the CSF above or close to the literature MIC values.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Doripenem has also completed two phase I studies in healthy volunteers with a number of different dosing regimens." | ( Doripenem: S 4661. , 2003) | 2.67 |
| "Recently, PK/PD (pharmacokinetics/pharmacodynamics) analysis for the antimicrobial dosage method became one of the popular categories in chemotherapy and infectious disease societies world wide." | ( [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory]. Kobayashi, Y; Sumitani, Y, 2007) | 0.57 |
| " Dosing regimens in mice were designed to approximate the free time above MIC (fT>MIC) observed with 500 mg doripenem every 8 h given as either a 1-h or 4-h intravenous infusion in humans." | ( In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Banevicius, MA; Kim, A; Nicolau, DP, 2008) | 0.83 |
| " These results should help to achieve a better understanding of the peritoneal pharmacodynamics of doripenem while also helping to rationalize and optimize the dosing regimen for intra-abdominal infections." | ( Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T, 2008) | 0.85 |
| " These results provide guidance for constructing a PK-PD-based strategy for dosing guidance for tailoring doripenem regimens." | ( Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Honda, N; Ikawa, K; Kumon, H; Monden, K; Morikawa, N; Uehara, S; Yamada, Y, 2009) | 0.81 |
| "This article reviews available information on doripenem in the management of patients with complicated bacterial infections, including its chemistry, spectrum of activity, resistance mechanisms, pharmacokinetics, pharmacodynamics, drug interactions, therapeutic efficacy, tolerability, and dosing and administration." | ( Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Lancaster, JW; Matthews, SJ, 2009) | 2.05 |
| " Some of the dosing regimens identified have been validated as effective in phase 3 clinical studies (500 mg infused over 1 h every 8 h for complicated intra-abdominal infections), whereas others (1000 mg infused over 4 h every 8 h for hospital-acquired pneumonia) are undergoing clinical evaluation." | ( Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Ambrose, PG; Andes, DR; Bhavnani, SM; Van Wart, SA, 2009) | 0.6 |
| " Currently unanswered questions regarding doripenem include the utility and dosing in neonatal, pediatric, and cystic fibrosis populations and specific dosage recommendations for patients receiving hemodialysis, peritoneal dialysis, or continuous renal replacement therapies." | ( Doripenem. Depestel, DD; Paterson, DL, 2009) | 2.06 |
| " Doripenem did not accumulate with repeated dosing over 7 days." | ( Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. Cirillo, I; Natarajan, J; Redman, R; Solanki, B; Turner, K; Vaccaro, N, 2009) | 1.52 |
| " As new pharmacokinetic data emerge, clarification of the pharmacokinetic/pharmacodynamic (PK/PD) profile of colistin as well as appropriate dosing seems urgent, while development of resistance must be carefully monitored." | ( Multidrug-resistant Gram-negative infections: what are the treatment options? Giamarellou, H; Poulakou, G, 2009) | 0.35 |
| "The aim of this study was to obtain information on effective dosage regimens of doripenem by a modeling and simulation approach based on pharmacokinetic (PK)/pharmacodynamic (PD) theory." | ( Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem. Katsube, T; Takano, M; Wajima, T; Yamano, Y; Yano, Y, 2010) | 0.8 |
| " Doripenem concentrations in pre- and post-membrane blood (plasma) samples collected at specified times during one dosing interval were measured in order to calculate pharmacokinetic parameters and clearance via hemodiafiltration." | ( Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Goto, K; Hagiwara, S; Hidaka, S; Iwasaka, H; Noguchi, T, 2010) | 2.71 |
| " Monte Carlo simulations were utilized to determine the appropriateness of several doripenem dosing regimens based on the probability of attaining the critical drug exposure metric of time that drug concentrations remain above the drug MIC (T>MIC) for 35% (and lower thresholds) of the dosing interval in >80 to 90% of the population (T>MIC 35% target)." | ( Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Flamm, R; Kaniga, K; Nandy, P; Samtani, MN, 2010) | 0.85 |
| "A spectrophotometric method was developed for the quantitative determination of doripenem in pharmaceutical dosage form (DORIBAX) in the presence of its degradation products." | ( The UV-derivative spectrophotometry for the determination of doripenem in the presence of its degradation products. Cielecka-Piontek, J; Jelińska, A, 2010) | 0.83 |
| " Its high stability in solution render it extremely flexible for dosing and infusion time." | ( The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem. Mazzei, T, 2010) | 0.59 |
| " Doripenem dosage regimens for patients receiving CRRT thus need to be adjusted." | ( Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. Balis, D; Cirillo, I; Matzke, GR; Redman, R; Vaccaro, N, 2011) | 1.49 |
| " Upon obtaining these results and several pharmacokinetic parameters, we attempted to optimize the dosing regimen of doripenem for hemodialysis patients." | ( Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis. Hirata, S; Kadowaki, D; Nishi, K; Tanoue, K, 2011) | 0.97 |
| "This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity." | ( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, ) | 0.13 |
| " A 5,000 patient Monte Carlo simulation was performed for each regimen and PD targets were defined as free drug concentrations above the MIC for at least 40% of the dosing interval." | ( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, ) | 0.13 |
| " Simulating two dosing scenarios gave doripenem levels in the CSF above or close to the literature MIC values." | ( Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. Archontaki, H; Boutos, N; Charkoftaki, G; Dimaraki, E; Dokoumetzidis, A; Margetis, K; Markantonis, S; Nalda-Molina, R; Sakas, D; Skoutelis, A; Valsami, G; Vryonis, E, 2012) | 0.97 |
| " A pharmacokinetic model with peripheral elimination described the data adequately and was tentatively used to predict concentration-versus-time profiles and pharmacokinetic-pharmacodynamic (PK-PD) target attainment in patients under various dosing regimens." | ( Modeling approach to characterize intraocular doripenem pharmacokinetics after intravenous administration to rabbits, with tentative extrapolation to humans. Adier, C; Couet, W; Goldschmidt, P; Grégoire, N; Lamarche, I; Laroche, L; Marchand, S; Semoun, O, 2012) | 0.64 |
| " Combinations at the highest dosage regimens resulted in undetectable bacterial counts at 72 h in 5 of 8 cases (4 isolates at 2 inocula)." | ( The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Bergen, PJ; Bulitta, JB; Davis, K; Deris, ZZ; Forrest, A; Jacob, J; Ku, CK; Li, J; Nation, RL; Paterson, DL; Poudyal, A; Soon, RL; Tsuji, BT; Velkov, T; Yu, HH, 2012) | 0.66 |
| "To compare the abilities of doripenem and ciprofloxacin to restrict the enrichment of resistant Pseudomonas aeruginosa, multiple antibiotic dosing regimens were simulated in an in vitro model at comparable ratios of the 24 h AUC (AUC24) to the MIC." | ( Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH, 2013) | 0.91 |
| "Doripenem- and ciprofloxacin-resistant mutants were enriched at antibiotic concentrations that fell into the mutant selection window for ≥ 45% and ≥ 60% of the dosing interval, respectively." | ( Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH, 2013) | 2.06 |
| " We sought to describe the population pharmacokinetics of doripenem in critically ill patients with nosocomial pneumonia and then to use Monte Carlo dosing simulations to procure clinically relevant dosing recommendations for that population." | ( Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Lipman, J; Roberts, JA, 2013) | 1.07 |
| " PK parameters were utilized to simulate free-drug profiles for various regimens in PD studies, from which the percentage of the dosing interval for which free-drug concentrations exceed the MIC of the targeted strain (%fT>MIC) was calculated." | ( Pharmacodynamic variability beyond that explained by MICs. Forrest, A; Ly, NS; Rao, G; Soon, RL; Tsuji, B; Wollenberg, L; Yang, K, 2013) | 0.39 |
| " The probability of pharmacodynamic target attainment was calculated over a range of minimum inhibitory concentrations (MICs), assuming a target of 35% of the dosing interval that unbound drug concentrations remain above the MIC." | ( Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Bhalodi, AA; Keel, RA; Kuti, JL; Lodise, TP; Nicolau, DP; Quintiliani, R, 2013) | 0.71 |
| " Optimal dosing regimens should be selected based on underlying renal function and suspected MIC of the infecting pathogen." | ( Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Bhalodi, AA; Keel, RA; Kuti, JL; Lodise, TP; Nicolau, DP; Quintiliani, R, 2013) | 0.71 |
| " Geometric means of maximum plasma concentration, area under the plasma concentration-time curve over the dosing interval at steady state, time to reach maximum plasma concentration, and terminal elimination half-life for 500 mg doripenem as a 1-h infusion were 22." | ( Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia. Chida, K; Harada, M; Inui, N; Matsuo, Y; Nakamura, Y; Suda, T; Wajima, T, 2013) | 0.87 |
| "The goal of this study was to evaluate our current dosing strategy for cefepime and the formulary carbapenem (imipenem) compared with meropenem and doripenem to determine the best dosing strategy for achieving maximal pharmacodynamic activity against an institution-specific population of P aeruginosa isolates." | ( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013) | 0.59 |
| " Cefepime dosing was increased from 2 g q12h SI to 2 g q8h PI, a 52% increase in drug acquisition cost." | ( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013) | 0.39 |
| "Antimicrobial stewardship programs should consider pharmacodynamic modeling to select the optimal dosing strategies to guide therapy in an era of escalating antimicrobial resistance." | ( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013) | 0.39 |
| " However, currently approved dosing regimens provide adequate pharmacodynamic exposures for susceptible bacteria in obese patients." | ( Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB, 2014) | 0.65 |
| "Doripenem is a newer carbapenem with little data available to guide effective dosing during renal replacement therapy in critically ill patients." | ( Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Bulitta, JB; Dunlop, R; Hayashi, Y; Jarrett, P; Lassig-Smith, M; Lipman, J; Roberts, JA; Roberts, NA; Starr, T; Stuart, J; Udy, AA; Wallis, SC, 2014) | 3.29 |
| " In cases of acute kidney injury, dosing of doripenem depends on creatinine clearance and requires adjustments." | ( The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis. Gaszynski, T; Gaszynski, W; Tokarz, A; Wieczorek, A, 2014) | 1.22 |
| "In vitro static concentration time-kill (SCTK) studies are a cornerstone for antibiotic development and designing dosage regimens." | ( Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies. Bulitta, JB; Cheah, SE; Li, J; Nation, RL, 2015) | 0.42 |
| " These dosing regimens also provide sufficient exposure to doripenem from the viewpoint of the percentage of time above the minimum inhibitory concentration." | ( Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment. Ishibashi, T; Kubota, R; Matsuo, Y; Wajima, T, 2015) | 0.95 |
| "The aim of this paper was to predict the pharmacokinetics of doripenem in pediatrics from adult pharmacokinetic data and to investigate dosing regimens in pediatrics using Monte-Carlo pharmacokinetics/pharmacodynamics (PK/PD) simulations prior to the initiation of pediatric clinical trials." | ( Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients. Ishibashi, T; Matsuo, Y; Shimamura, K; Wajima, T, 2015) | 0.91 |
| " One of the reasons (carba)penems are seldom used for treatment of TB is the high dosage levels required, often at the therapeutic limits." | ( Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U, 2015) | 0.42 |
| " However, limited data currently exist to guide optimal dosing in this scenario." | ( Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. Abd Rahman, AN; Abdul-Aziz, MH; Lipman, J; Mat-Nor, MB; Roberts, JA; Staatz, CE; Sulaiman, H; Wallis, SC, 2016) | 0.72 |
| " While the initial dosing recommendation for renally competent patients and patients undergoing continuous renal replacement therapy (cRRT) was 500 mg every 8 h (q8h), the dose for renally competent patients was updated to 1 g q8h in June 2012." | ( Doripenem Treatment during Continuous Renal Replacement Therapy. Fritsch, A; Jaehde, U; Jäger, W; Jilch, S; Lemmerer, R; Maier-Salamon, A; Saria, K; Thalhammer, F; Unger, M; Vossen, MG; Wenisch, JM; Zuba, C, 2015) | 1.86 |
| " Higher dosage of antibiotics has recently been used, and high-dose doripenem (DRPM; 3 g daily) was approved for use in Japan in April 2011." | ( Clinical efficacy and safety of high-dose doripenem in Japanese patients with pneumonia. Akata, K; Ishimoto, H; Kawanami, T; Kido, T; Mukae, H; Naito, K; Nishida, C; Noguchi, S; Sakamoto, N; Yamasaki, K; Yatera, K, 2016) | 0.93 |
| " The MCS indicated that more intensive doripenem dosing schemes should be considered for organisms with MIC values in excess of 2 mg/L." | ( Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. Abraham, P; Chaar, M; Chester, K; Curzio, K; Huang, V; Lockwood, A; Lodise, TP; Morse, B; Pai, MP; Patka, J; Rabinovich, M; Rahbar, AJ; Salomone, J; Williams, B, 2016) | 0.96 |
| " Among these patients, the MCS analyses suggest that current dosing strategies may be ineffective when the MIC value for the infecting pathogen is expected to be above 2 mg/L." | ( Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. Abraham, P; Chaar, M; Chester, K; Curzio, K; Huang, V; Lockwood, A; Lodise, TP; Morse, B; Pai, MP; Patka, J; Rabinovich, M; Rahbar, AJ; Salomone, J; Williams, B, 2016) | 0.69 |
| "Doripenem population pharmacokinetics and dosing recommendations are limited in obesity." | ( Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients. Cheatham, SC; Chung, EK; Fleming, MR; Kays, MB, 2017) | 2.15 |
| " Using 40% fT>MIC, PTA was >90% for all simulated dosing regimens at MICs ≤2 mg/L." | ( Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients. Cheatham, SC; Chung, EK; Fleming, MR; Kays, MB, 2017) | 0.71 |
| " Currently approved dosing regimens provide adequate pharmacodynamic exposures at 40% fT>MIC for susceptible bacteria in obese patients." | ( Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients. Cheatham, SC; Chung, EK; Fleming, MR; Kays, MB, 2017) | 0.71 |
| "Doripenem (DRPM) is a broad-spectrum antibacterial agent often used as empirical therapy for critically ill patients, although there is a lack of studies validating the recommended dosage regimen for patients admitted to intensive care unit (ICU), based on pharmacokinetic (PK)/pharmacodynamic (PD) index." | ( Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient. Goto, K; Ito, K; Itoh, H; Kaneko, T; Kurogi, S; Nonoshita, K; Ohchi, Y; Sato, Y; Suzuki, Y; Tanaka, R; Ueno, T; Yasuda, N, 2017) | 2.16 |
| " The aim of this study is to investigate the pharmacokinetic (PK) properties of doripenem and explore optimal dosing regimens in patients with normal or enhanced renal function according to various minimum inhibitory concentrations (MICs)." | ( Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function. Choe, S; Kim, DJ; Kim, SW; Lee, DH; Zang, DY, 2018) | 1.03 |
| " The population PK parameter estimates were used in Monte Carlo simulations to explore optimal dosing regimens for a probability of target attainment of 90% at 40% fTMIC (free drug concentrations above MIC)." | ( Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function. Choe, S; Kim, DJ; Kim, SW; Lee, DH; Zang, DY, 2018) | 0.8 |
| "These results suggest that dosage adjustment such as increasing the dose or lengthening the infusion time should be considered in patients with normal or enhanced renal function." | ( Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function. Choe, S; Kim, DJ; Kim, SW; Lee, DH; Zang, DY, 2018) | 0.8 |
| " aeruginosa, 2 was shown to have dose-dependent efficacy at 50 and 100 mg/kg q6h dosing in a mouse thigh infection model." | ( A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. Bethel, CR; Bonomo, RA; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Kumar, V; Marshall, SH; Papp-Wallace, KM; Perez, F; Plummer, MS; Spencer, EJ; van den Akker, F; van Duin, D, 2021) | 0.62 |
| " Thus, it is necessary to decide the antibiotic dosage considering the CRRT clearance in addition to residual renal function." | ( UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy. Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N, 2023) | 1.16 |
| Class | Description |
|---|---|
| carbapenems | The class of beta-lactam antibiotics that whose members have a carbapenem skeleton which is variously substituted at positions 3, 4, and 6. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 0.8709 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 14.1254 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 33.4983 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.9497 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 20.1215 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 18.8336 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| G | Vesicular stomatitis virus | Potency | 10.9640 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 2.5119 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 55.1965 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 28.1838 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 9.3590 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Interferon beta | Homo sapiens (human) | Potency | 10.9640 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 10.9640 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 10.9640 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 10.9640 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 (µMol) | 316.2280 | 0.1200 | 4.0480 | 10.0000 | AID1207367 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 (µMol) | 316.2280 | 0.1200 | 4.0480 | 10.0000 | AID1207367 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 6,477.5750 | 0.0009 | 1.9014 | 10.0000 | AID1207461; AID1207521 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 (µMol) | 1.9953 | 0.0003 | 2.2545 | 9.6000 | AID1207555 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 (µMol) | 1,584.8900 | 0.0003 | 3.6484 | 9.2000 | AID1207307 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-lactamase | Enterobacter cloacae | Km | 9.6000 | 2.9000 | 6.4364 | 9.8000 | AID495693 |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | Km | 4.3000 | 4.2000 | 4.2500 | 4.3000 | AID495687 |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | Km | 1.8000 | 0.5000 | 4.2444 | 8.0000 | AID495747 |
| Beta-lactamase TEM | Escherichia coli | Km | 5.4000 | 5.4000 | 6.3000 | 7.2000 | AID495686 |
| Beta-lactamase | Escherichia coli | Km | 0.0046 | 0.0046 | 1.4149 | 4.5000 | AID495746 |
| Beta-lactamase | Serratia marcescens | Km | 8.2000 | 2.2000 | 4.6000 | 8.2000 | AID495696 |
| Beta-lactamase IMP-1 | Pseudomonas aeruginosa | Km | 30.0000 | 6.5000 | 6.5000 | 6.5000 | AID495698 |
| Beta-lactamase | Escherichia coli | Km | 7.1000 | 7.1000 | 8.1667 | 8.7000 | AID495688 |
| Carbapenem-hydrolyzing beta-lactamase KPC | Klebsiella pneumoniae | Km | 1.6000 | 1.6000 | 3.8000 | 6.0000 | AID495695 |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | Km | 83.0000 | 2.0000 | 6.6500 | 9.4000 | AID495697 |
| Beta-lactamase | Acinetobacter baumannii | Km | 55.9000 | 1.3000 | 3.8000 | 9.6000 | AID495699; AID495700 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID534607 | Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534703 | Antimicrobial activity against Finegoldia magna by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495700 | Activity of Acinetobacter baumannii OXA-23 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID518370 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID534867 | Antimicrobial activity against ESBL producing Proteus mirabilis assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID518384 | Antimicrobial activity against Streptococcus sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID587027 | Clearance in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID574032 | Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID425093 | Antimicrobial activity against Fusobacterium varium isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534445 | Antimicrobial activity against Bifidobacterium adolescentis ATCC 15703 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID533128 | Antimicrobial activity against Bacteroides caccae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID565923 | fT>MIC in Klebsiella pneumoniae isolate KPC 359 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID518375 | Antimicrobial activity against Haemophilus sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID495704 | Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID529811 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 968 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524094 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P376 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534469 | Antimicrobial activity against Parabacteroides distasonis ATCC 8503 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID535131 | Antimicrobial activity against Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID533361 | Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523906 | Antibacterial activity against Acinetobacter baumannii A911 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530190 | Antibacterial activity against Pseudomonas aeruginosa isolate 1050 assessed as log reduction in bacterial count at 4 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID518363 | Antimicrobial activity against Citrobacter freundii clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID425100 | Antimicrobial activity against Peptoniphilus asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529979 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 979 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425328 | Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529980 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1036 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523920 | Antibacterial activity against Acinetobacter baumannii A885 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556925 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523583 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524426 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with complicated urinary tract infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID433004 | Antibacterial activity against Corynebacterium urealyticum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID518368 | Antimicrobial activity against Morganella morganii clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID433150 | Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523913 | Antibacterial activity against Acinetobacter baumannii A928 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535165 | Antimicrobial activity against Acinetobacter assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID533377 | Antimicrobial activity against Bacteroides merdae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID529799 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 979 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID562757 | Ratio of Kcat to Km for Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID433007 | Antibacterial activity against Corynebacterium simulans isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID433157 | Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523918 | Antibacterial activity against Acinetobacter baumannii A929 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533412 | Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID580408 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as asymptomatic bacteriuria at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID565920 | fT>MIC in Klebsiella pneumoniae isolate KPC 356 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID530025 | Volume of distribution in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556720 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID535844 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID433361 | Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID1318925 | Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 101243 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID524414 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with complicated urinary tract infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID573597 | Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID564678 | fAUC in ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID573557 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID588129 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID1155045 | Inhibition of Staphylococcus aureus MraY by fluorescence assay | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5 | Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. |
| AID580406 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as insomnia at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID573834 | Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID433009 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556743 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534687 | Antimicrobial activity against Bacteroides vulgatus by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534700 | Antimicrobial activity against Fusobacterium mortiferum by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523602 | Antibacterial activity against Pseudomonas aeruginosa P365 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534691 | Antimicrobial activity against Prevotella intermedia by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556205 | T>MIC in Moraxella catarrhalis-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523769 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495741 | Kcat/Km ratio of Serratia marcescens SME-3 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID533401 | Antimicrobial activity against Clostridium subterminale by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID425103 | Antimicrobial activity against Clostridium innocuum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID495746 | Inhibition of Escherichia coli CMY-2 assessed as inhibition of nitrocefin hydrolysis | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID425084 | Antimicrobial activity against beta lactamase-positive Prevotella melaninogenica isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID523903 | Antibacterial activity against Acinetobacter baumannii A865 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534451 | Antimicrobial activity against Propionibacterium acnes ATCC 11828 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534918 | Antimicrobial activity against Serratia marcescens by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID530018 | Cmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534641 | Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID556471 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425105 | Antimicrobial activity against Clostridium bifermentans isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529782 | Antibacterial activity against Pseudomonas aeruginosa isolate 896 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433155 | Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID564499 | fT>MIC in Pseudomonas aeruginosa selected at 8 ug/ml MIC infected human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID533425 | Antimicrobial activity against Peptostreptococcus sp. by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID433149 | Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID530021 | Tmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524074 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P373 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID1318920 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 259-96918 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID534900 | Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID586232 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID524407 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID523578 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523930 | Antibacterial activity against beta-lactamase-negative Escherichia coli E350 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495675 | Antimicrobial activity against wild type Serratia marcescens OC 7555 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556916 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495677 | Antimicrobial activity against Enterobacter cloacae OC 4080 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID535128 | Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534610 | Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534919 | Antimicrobial activity against Ceftazidime susceptible Serratia marcescens by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425081 | Antimicrobial activity against beta lactamase-positive Prevotella disiens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534702 | Antimicrobial activity against Desulfovibrio desulfuricans by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495697 | Activity of Pseudomonas aeruginosa VIM-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523599 | Antibacterial activity against Pseudomonas aeruginosa P328 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530006 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 931 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534701 | Antimicrobial activity against Fusobacterium sp. by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID425106 | Antimicrobial activity against Clostridium clostridioforme isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID425102 | Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID433359 | Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID530181 | Cmax in healthy human at 500 mg administered as as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID557153 | Antimicrobial activity against Escherichia coli 2062716 B-R isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID558423 | Antimicrobial activity against Burkholderia pseudomallei by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activity of doripenem against Burkholderia pseudomallei. |
| AID433374 | Antibacterial activity against Bacteroides fragilis ATCC 25285 after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID573786 | Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID547996 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237C mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID425082 | Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534880 | Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425329 | Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID524421 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with urinary tract infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID529989 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1006 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1207307 | Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform | |||
| AID546621 | Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID534623 | Antimicrobial activity against ESBL producing Escherichia coli by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524313 | Antibacterial activity against Acinetobacter baumannii A864 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495696 | Activity of Serratia marcescens SME-3 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556937 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID556924 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID530031 | Half-life in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524081 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P334 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433019 | Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534414 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID533421 | Antimicrobial activity against Anaerococcus prevotii by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524425 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with complicated urinary tract infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID533413 | Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID530198 | Antibacterial activity against Pseudomonas aeruginosa isolate 1060 by fractionation study | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425095 | Antimicrobial activity against Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534478 | Antimicrobial activity against Prevotella buccae ATCC 33574 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534898 | Antimicrobial activity against Citrobacter by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID564452 | Antimicrobial activity against Pseudomonas aeruginosa isolate 944 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID556730 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID518389 | Antimicrobial activity against Acinetobacter sp. clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID523600 | Antibacterial activity against Pseudomonas aeruginosa P352 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533408 | Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID587045 | Non-renal clearance in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID524117 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A891 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID586233 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID556199 | T>MIC in Pseudomonas aeruginosa infected in thigh of neutropenic mouse at 500 mg/kg, iv administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID518387 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID529780 | Antibacterial activity against Pseudomonas aeruginosa isolate 1050 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID518372 | Antimicrobial activity against Acinetobacter baumannii clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID534603 | Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID518377 | Antimicrobial activity against Enterococcus faecalis clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID535841 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID548040 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBK SK(+) by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID524277 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530195 | Antibacterial activity against Pseudomonas aeruginosa isolate 931 by fractionation study | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573397 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529807 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 936 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID518362 | Antimicrobial activity against Klebsiella oxytoca clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID529982 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 931 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1155044 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as growth inhibition after 20 hrs by microdilution method | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5 | Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. |
| AID534630 | Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523726 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E347 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495740 | Kcat/Km ratio of Klebsiella pneumoniae KPC-2 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID557146 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID557164 | Antimicrobial activity against Escherichia coli 1655646 A-Y isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID519808 | Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID557154 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523925 | Antibacterial activity against beta-lactamase-negative Escherichia coli E344 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556222 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID510509 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID556210 | Drug excretion in pyelonephritis patient urine at 250 mg/kg, iv administered every 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1296370 | Activity at Mycobacterium tuberculosis beta lactamase BlaC expressed in Escherichia coli by spectrophotometric method | 2016 | Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7 | Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC. |
| AID530189 | Antibacterial activity against Pseudomonas aeruginosa isolate assessed as log reduction in bacterial count at 16 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556918 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID535839 | Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID535838 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID523755 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E418 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529977 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1082 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID574471 | Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID534464 | Antimicrobial activity against Bacteroides fragilis GAI 7955 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573592 | Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID433008 | Antibacterial activity against Corynebacterium xerosis isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID557143 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID535163 | Antimicrobial activity against imipenem susceptible Acinetobacter by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID518373 | Antimicrobial activity against Burkholderia cepacia clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID523568 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530196 | Antibacterial activity against Pseudomonas aeruginosa isolate 944 by fractionation study | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433202 | Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534704 | Antimicrobial activity against Parvimonas micra by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID574042 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID495728 | Activity of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID534698 | Antimicrobial activity against Fusobacterium necrophorum by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID425086 | Antimicrobial activity against beta lactamase-positive Prevotella corporis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID519803 | Antimicrobial activity against Escherichia coli MC4100 by CLSI protocol based broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID530185 | AUC in healthy human at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID562754 | Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID535126 | Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID495671 | Antimicrobial activity against wild type Escherichia coli ATCC 25922 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID425094 | Antimicrobial activity against beta lactamase-positive Fusobacterium mortiferum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID433000 | Antibacterial activity against Corynebacterium amycolatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID433152 | Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID518392 | Antimicrobial activity against Klebsiella pneumoniae clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID518399 | T>MIC in bacilli infected patients with renal impairment at 500 mg administered as 1 hr infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID529781 | Antibacterial activity against Pseudomonas aeruginosa isolate 1060 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534428 | Antimicrobial activity against Atopobium parvulum VPI 0546 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573564 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID433003 | Antibacterial activity against Corynebacterium minutissimum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID495731 | Kcat/Km ratio of Escherichia coli TEM-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID534452 | Antimicrobial activity against Propionibacterium granulosum ATCC 25564 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524084 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P328 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID580384 | Antibacterial activity against Klebsiella pneumoniae infected in microbiologically evaluable patient with UTI assessed as cure rate at 500 mg, iv administered every 8 hrs for 10 days measured at test-of-cure visit | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID547793 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237V mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID564673 | fT>MIC in Pseudomonas aeruginosa selected at 16 ug/ml MIC infected ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID425101 | Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID510502 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID580427 | Drug related treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as >=1 adverse event at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID565919 | fT>MIC in Klebsiella pneumoniae isolate KPC 356 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID425092 | Antimicrobial activity against Fusobacterium necrophorum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID564497 | fT>MIC in Pseudomonas aeruginosa selected at 2 ug/ml MIC infected human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534709 | Antimicrobial activity against Clostridium difficile by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534672 | Antimicrobial activity against Porphyromonas asaccharolyticus ATCC 25260 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID564463 | Antimicrobial activity against Pseudomonas aeruginosa isolate 927 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID433001 | Antibacterial activity against Corynebacterium aurimucosum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID580497 | Drug related treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as phlebitis at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID529772 | Antibacterial activity against Pseudomonas aeruginosa isolate 1052 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID565932 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 354 in immunocompromized mouse thigh infection model assessed as decrease in bacterial density in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID556474 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID573784 | Antibacterial activity against Prevotella bivia by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523735 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E424 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID546619 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID433159 | Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534644 | Antimicrobial activity against Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID564461 | Antimicrobial activity against Pseudomonas aeruginosa isolate 856 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529971 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 886 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573593 | Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID524325 | Antibacterial activity against Acinetobacter baumannii A908 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523768 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E420 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID588126 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID524077 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P320 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534471 | Antimicrobial activity against Bacteroides thetaiotaomicron ATCC 29741 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534685 | Antimicrobial activity against Parabacteroides distasonis by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID533396 | Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID518385 | Antimicrobial activity against Enterococcus faecalis clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID523571 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524105 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A849 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533405 | Antimicrobial activity against Clostridium tertium by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID511700 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA5513 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID533397 | Antimicrobial activity against Clostridium paraputrificum by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523739 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E452 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523569 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495703 | Kcat/Km ratio of Escherichia coli CTX-M-15 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID524411 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with urinary tract infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID565924 | fT>MIC in Klebsiella pneumoniae isolate KPC 359 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID518386 | Antimicrobial activity against Streptococcus pneumoniae clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID534442 | Antimicrobial activity against Clostridium sordellii ATCC 9714 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID433170 | Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID518365 | Antimicrobial activity against Enterobacter cloacae clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID529958 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 931 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID557177 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID535832 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID433002 | Antibacterial activity against Corynebacterium jeikeium isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534692 | Antimicrobial activity against Prevotella sp. by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534699 | Antimicrobial activity against Fusobacterium varium by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID535130 | Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425099 | Antimicrobial activity against Anaerococcus tetradius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID530179 | Cmax in healthy human at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556202 | T>MIC in ceftazidime-susceptible Acinetobacter spp.-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425321 | Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID565928 | fT>MIC in Klebsiella pneumoniae isolate KPC 361 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID518369 | Antimicrobial activity against Serratia marcescens clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID574461 | Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID533373 | Antimicrobial activity against Bacteroides eggerthii by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524305 | Antibacterial activity against Pseudomonas aeruginosa P363 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433013 | Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524083 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P338 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556488 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495718 | Activity of Escherichia coli CTX-M-15 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID425077 | Antimicrobial activity against beta lactamase-positive Bacteroides ovatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID546620 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID556706 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495739 | Kcat/Km ratio of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556204 | T>MIC in Pseudomonas aeruginosa-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID562756 | Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID580404 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as nausea at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID519802 | Inhibition of Bocillin FL binding to PBP6 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID524082 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P337 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524279 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523929 | Antibacterial activity against beta-lactamase-negative Escherichia coli E348 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530194 | Antibacterial activity against Pseudomonas aeruginosa isolate at 8 to 16 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534695 | Antimicrobial activity against Porphyromonas gingivalis by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID530180 | Cmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 5.5, 2.25, 4.5, 4.5, 4.5, 4.5, 0.75, and 0.375 mg/kg given at 0, 0.5, 1.5, 2.5, 3.5, 4.5, 6, and 7.5 h over 24 h | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529764 | Antibacterial activity against Pseudomonas aeruginosa isolate 993 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524311 | Antibacterial activity against Acinetobacter baumannii A848 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587031 | AUC (0 to 12 hrs) in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID519801 | Inhibition of Bocillin FL binding to PBP5 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID534444 | Antimicrobial activity against Actinomyces odontolyticus GAI 91002 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534458 | Antimicrobial activity against Lactobacillus reuteri JCM 1112 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556492 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495743 | Kcat/Km ratio of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523767 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E417 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587043 | Clearance in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID425320 | Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID432992 | Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID511713 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA1166 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID425104 | Antimicrobial activity against Clostridium ramosum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID573590 | Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID495721 | Activity of Escherichia coli CMY-2 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523754 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E362 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524320 | Antibacterial activity against Acinetobacter baumannii A849 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535365 | Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425085 | Antimicrobial activity against beta lactamase-positive Prevotella denticola isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID518378 | Antimicrobial activity against Staphylococcus sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID523912 | Antibacterial activity against Acinetobacter baumannii A896 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523764 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534473 | Antimicrobial activity against Bacteroides eggerthii ATCC 27754 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID530033 | Half-life in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID511698 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA27853 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID534441 | Antimicrobial activity against Clostridium septicum ATCC 12464 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556722 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID518361 | Antimicrobial activity against Klebsiella pneumoniae clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID558422 | Antimicrobial activity against Burkholderia pseudomallei by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activity of doripenem against Burkholderia pseudomallei. |
| AID556915 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529793 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1062 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524269 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529954 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 906 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534437 | Antimicrobial activity against Streptococcus intermedius ATCC 27335 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID565936 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 361 in immunocompromized mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 2 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID534470 | Antimicrobial activity against Bacteroides ovatus ATCC 8483 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524299 | Antibacterial activity against Pseudomonas aeruginosa P328 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433161 | Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID425080 | Antimicrobial activity against beta lactamase-positive Prevotella bivia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID565926 | fT>MIC in Klebsiella pneumoniae isolate KPC 360 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID534661 | Antimicrobial activity against Proteus mirabilis by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534688 | Antimicrobial activity against Bacteroides caccae by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID518382 | Antimicrobial activity against Coagulase-negative oxacillin-susceptible Staphylococcus sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID524429 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID573837 | Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID556929 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425075 | Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID530034 | Clearance in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524075 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P335 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524274 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID518360 | Antimicrobial activity against Escherichia coli clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID524290 | Antibacterial activity against Pseudomonas aeruginosa P335 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534694 | Antimicrobial activity against Porphyromonas asaccharolyticus by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID519809 | Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID433151 | Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID425098 | Antimicrobial activity against Anaerococcus prevotii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529983 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 944 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID564465 | Antimicrobial activity against Pseudomonas aeruginosa isolate 971 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID556711 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524099 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A865 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID565929 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 354 in immunocompetent mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 2 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID523716 | Antibacterial activity against Acinetobacter baumannii A929 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556751 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID530019 | Tmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID588132 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID425113 | Antimicrobial activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID524091 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P370 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425120 | Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID548028 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237K mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID556727 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID432998 | Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID557155 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID564460 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1006 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID518390 | Antimicrobial activity against Enterobacter cloacae clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID556238 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID432990 | Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534878 | Antimicrobial activity against Enterobacter cloacae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID556931 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495730 | Activity of Acinetobacter baumannii OXA-23 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523757 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID557162 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495669 | Antimicrobial activity against Escherichia coli OC 11732 expressing extended-spectrum beta-lactamase CTX-M-15 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID433165 | Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523419 | Antibacterial activity against beta-lactamase-negative Escherichia coli E346 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID557160 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID530187 | Antibacterial activity against Pseudomonas aeruginosa isolate assessed as log reduction in bacterial count at 0.125 to 2 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID587039 | AUC (0 to 12 hrs) in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID523905 | Antibacterial activity against Acinetobacter baumannii A867 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529951 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1005 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529973 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1062 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495682 | Antimicrobial activity against Pseudomonas aeruginosa OC 12115 expressing beta-lactamase SPM-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID432991 | Antibacterial activity against Clostridium difficile ATCC 700057 after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534456 | Antimicrobial activity against Lactobacillus fermentum JCM 1173 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495715 | Kcat/Km ratio of Acinetobacter baumannii OXA-23 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID574027 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID425331 | Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID524417 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID432989 | Antibacterial activity against Enterococcus faecalis after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID547777 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237G mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID523766 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523945 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529961 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1060 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID564455 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1095 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534480 | Antimicrobial activity against Prevotella heparinolytica ATCC 35895 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID564500 | fT>MIC in Pseudomonas aeruginosa selected at 16 ug/ml MIC infected human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID524119 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A901 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587034 | Volume of distribution at steady state in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID524109 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A928 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533360 | Antimicrobial activity against Bacteroides ovatus assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523904 | Antibacterial activity against Acinetobacter baumannii A851 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523897 | Antibacterial activity against Pseudomonas aeruginosa P358 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID518383 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID557152 | Antimicrobial activity against Serratia marcescens 2297260 B-U isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID574006 | Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID519811 | Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID535164 | Antimicrobial activity against imipenem non-susceptible Acinetobacter by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523926 | Antibacterial activity against beta-lactamase-negative Escherichia coli E345 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533135 | Antimicrobial activity against Bacteroides ovatus by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524120 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A903 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564459 | Antimicrobial activity against Pseudomonas aeruginosa isolate 988 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID587041 | Terminal half life in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID580493 | Drug related treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as upper abdominal pain at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID524301 | Antibacterial activity against Pseudomonas aeruginosa P353 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID573825 | Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534621 | Antimicrobial activity against Escherichia coli by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID518364 | Antimicrobial activity against Citrobacter koseri clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID432995 | Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534693 | Antimicrobial activity against Prevotella melaninogenica by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID511711 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA707 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID534710 | Antimicrobial activity against Clostridium perfringens by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID518380 | Antimicrobial activity against oxacillin-susceptible Staphylococcus aureus clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID523750 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E359 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587035 | Clearance in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID534416 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524431 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID533364 | Antimicrobial activity against Bacteroides thetaiotaomicron assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523736 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E425 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533126 | Antimicrobial activity against Bacteroides caccae assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID341089 | Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. |
| AID523902 | Antibacterial activity against Acinetobacter baumannii A864 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495723 | Activity of Enterobacter cloacae AmpC relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID433168 | Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID518366 | Antimicrobial activity against Enterobacter aerogenes clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID433158 | Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID529959 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 944 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524112 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A931 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533131 | Antimicrobial activity against Bacteroides fragilis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534476 | Antimicrobial activity against Sutterella wadsworthensis ATCC 51579 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523417 | Antibacterial activity against beta-lactamase-negative Escherichia coli E344 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID574050 | Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID547789 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237M mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID556207 | T>MIC in ampicillin-susceptible Haemophilus influenzae-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID533635 | Antimicrobial activity against Propionibacterium sp. by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534446 | Antimicrobial activity against Bifidobacterium bifidum JCM 1255 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573591 | Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID510511 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID518371 | Antimicrobial activity against Acinetobacter sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID425118 | Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529990 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 927 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529767 | Antibacterial activity against Pseudomonas aeruginosa isolate 886 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573785 | Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID580402 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as vomiting at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID588127 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID557147 | Antimicrobial activity against Staphylococcus epidermidis 1949822 B-J isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425090 | Antimicrobial activity against Porphyromonas levii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID433356 | Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556516 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1207521 | Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay | |||
| AID433177 | Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID529800 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1036 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573783 | Antibacterial activity against Prevotella buccae by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID557167 | Antimicrobial activity against Enterococcus faecalis 2215767-10 B-S isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID564491 | fT>MIC in Pseudomonas aeruginosa selected at 32 ug/ml MIC infected human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID587024 | AUC (0 to infinity) in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID565822 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 353 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID557170 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID587022 | Cmax in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID556919 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523559 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID518394 | Antimicrobial activity against Proteus mirabilis clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID557149 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433005 | Antibacterial activity against Corynebacterium striatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID425078 | Antimicrobial activity against beta lactamase-positive Bacteroides vulgatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529766 | Antibacterial activity against Pseudomonas aeruginosa isolate 869 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID580407 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as urinary tract infection at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID586234 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID556226 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID533634 | Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534409 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID588124 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID530010 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 896 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523917 | Antibacterial activity against Acinetobacter baumannii A897 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534433 | Antimicrobial activity against Peptostreptococcus anaerobius ATCC 27337 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495729 | Activity of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID574466 | Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID534690 | Antimicrobial activity against Odoribacter splanchnicus by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573572 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID533368 | Antimicrobial activity against Bacteroides uniformis assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID425079 | Antimicrobial activity against beta lactamase-positive Bacteroides distasonis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534884 | Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID564676 | fAUC in ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID523721 | Antibacterial activity against Acinetobacter baumannii A901 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID565938 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 354 in immunocompetent mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID524287 | Antibacterial activity against Pseudomonas aeruginosa P356 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524282 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495686 | Activity of Escherichia coli TEM-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523414 | Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 500 mg administered at 1 hr infusion regimen every 8 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID523720 | Antibacterial activity against Acinetobacter baumannii A894 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524078 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P322 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533389 | Antimicrobial activity against Clostridium perfringens by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID511708 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA9019 harboring gyrA D87G and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID524416 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID518381 | Antimicrobial activity against Coagulase-negative Staphylococcus sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID533393 | Antimicrobial activity against Clostridium innocuum by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID433017 | Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID533631 | Antimicrobial activity against Propionibacterium acnes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524104 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A892 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564490 | fT>MIC in Pseudomonas aeruginosa selected at 16 ug/ml MIC infected human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID535842 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID535366 | Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID556745 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID519815 | Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID518391 | Antimicrobial activity against Escherichia coli clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID1296367 | Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as first order rate constant for oxyanion formation by stopped-flow spectrofluorimetric method | 2016 | Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7 | Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC. |
| AID433153 | Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID564494 | fT>MIC in Pseudomonas aeruginosa selected at 8 ug/ml MIC infected ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID580394 | Antibacterial activity against doripenem-resistant Enterococcus avium | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID548016 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237D mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID433367 | Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID565832 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 360 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID565827 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 356 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID523894 | Antibacterial activity against Pseudomonas aeruginosa P363 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523943 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID557171 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523409 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 expressing derepressed chromosomal AmpC mutant by broth macrodilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID495678 | Antimicrobial activity against wild type Pseudomonas aeruginosa ATCC 27853 expressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID587025 | Terminal half life in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID524424 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with complicated urinary tract infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID580376 | Antibacterial activity against Enterococcus faecium | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID534662 | Antimicrobial activity against Non-ESBL Proteus mirabilis by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID557165 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524284 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534879 | Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524324 | Antibacterial activity against Acinetobacter baumannii A928 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556933 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID587021 | Tmax in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID534642 | Antimicrobial activity against Non-ESBL Klebsiella pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID533388 | Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524430 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID530002 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 906 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495683 | Antimicrobial activity against Pseudomonas aeruginosa OC 4083 expressing beta-lactamase OXA-10 and containing Oxacillinase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID529953 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1082 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523907 | Antibacterial activity against Acinetobacter baumannii A912 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529791 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 886 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433363 | Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523937 | Antibacterial activity against beta-lactamase-negative Escherichia coli E424 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534449 | Antimicrobial activity against Bifidobacterium pseudolongum ATCC 25526 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID547992 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Y mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID495691 | Activity of Escherichia coli CMY-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID495680 | Antimicrobial activity against Pseudomonas aeruginosa OC 13996 expressing beta-lactamase IMP-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523577 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534674 | Antimicrobial activity against Fusobacterium nucleatum ATCC 25586 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID425108 | Antimicrobial activity against Clostridium paraputrificum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID425322 | Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID574687 | Antimicrobial activity against Escherichia coli DH10B by Etest | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID534602 | Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID519810 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by CLSI protocol based broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID533365 | Antimicrobial activity against Bacteroides uniformis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523551 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523931 | Antibacterial activity against beta-lactamase-negative Escherichia coli E408 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530193 | Antibacterial activity against Pseudomonas aeruginosa isolate 944 at 4 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID533381 | Antimicrobial activity against Bacteroides nordii by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID573822 | Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID518374 | Antimicrobial activity against Stenotrophomonas maltophilia clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID523572 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523576 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID565836 | fT>MIC in Klebsiella pneumoniae isolate KPC 353 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID564493 | fT>MIC in Pseudomonas aeruginosa selected at 4 ug/ml MIC infected ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID556917 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID518388 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID524409 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with urinary tract infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID524418 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID586236 | Antimicrobial activity against Escherichia coli J53 harboring Klebsiella pneumoniae Kp7 beta-lactamase NDM-1 | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID557168 | Antimicrobial activity against Enterococcus faecalis 2297262-10 B-V isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534705 | Antimicrobial activity against Peptostreptococcus anaerobius by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524086 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P353 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID586231 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID495666 | Antimicrobial activity against Klebsiella pneumoniae OC 4238 overexpressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID425091 | Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID433179 | Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID564457 | Antimicrobial activity against Pseudomonas aeruginosa isolate 878 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID523922 | Antibacterial activity against Acinetobacter baumannii A894 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524296 | Antibacterial activity against Pseudomonas aeruginosa P334 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID547769 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBC SK(+) carrying wild type beta-lactamase KPC-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID574041 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID587042 | Volume of distribution at steady state in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID523729 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E408 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523733 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E415 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433173 | Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534408 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID565940 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 359 in immunocompetent mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 2 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID432999 | Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524106 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A910 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524072 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P356 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID510513 | Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID433016 | Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534864 | Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID433375 | Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID573581 | Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID556923 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433369 | Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID433171 | Antibacterial activity against multi drug-resistant Corynebacterium assessed as percent of susceptible isolates at =< 4 ug/ml by NCCLS M7-A6 method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID580491 | Drug related treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as diarrhea at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID495707 | Kcat/Km ratio of Pseudomonas aeruginosa AmpC | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID564674 | fT>MIC in Pseudomonas aeruginosa selected at 32 ug/ml MIC infected ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534430 | Antimicrobial activity against Parvimonas micra VPI 5464-1 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556951 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524092 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P341 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523752 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E419 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535140 | Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523549 | Antibacterial activity against beta-lactamase-negative Escherichia coli E425 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556954 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433190 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID535836 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID524593 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. |
| AID529950 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 935 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523552 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523540 | Antibacterial activity against beta-lactamase-negative Escherichia coli E348 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530192 | Antibacterial activity against Pseudomonas aeruginosa isolate 931 at 4 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID530197 | Antibacterial activity against Pseudomonas aeruginosa isolate 1050 by fractionation study | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID564454 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1060 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529952 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1052 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1782894 | Inhibition of Acinetobacter sp. strain ATCC 27244 PBP3 expressed in Escherichia coli BL21 (DE3) assessed as reduction in fluorescence intensity using Bocillin-protein as fluorescent substrate by SDS PAGE analysis | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. |
| AID519820 | Induction of morphological changes in Pseudomonas aeruginosa 27853 assessed as increase in cell length at antimicrobial MIC after 240 mins by microscopy | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID573801 | Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID432994 | Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID530029 | Elimination rate constant in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433366 | Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID535367 | Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID530000 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1052 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524318 | Antibacterial activity against Acinetobacter baumannii A912 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID574464 | Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID574462 | Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID573824 | Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID533424 | Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523598 | Antibacterial activity against Pseudomonas aeruginosa P338 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524316 | Antibacterial activity against Acinetobacter baumannii A867 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433376 | Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534697 | Antimicrobial activity against Fusobacterium nucleatum by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523747 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E484 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534627 | Antimicrobial activity against Non-ESBL Escherichia coli assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID580403 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as upper abdominal pain at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID529984 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1050 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534707 | Antimicrobial activity against Eggerthella lenta by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523718 | Antibacterial activity against Acinetobacter baumannii A885 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534479 | Antimicrobial activity against Prevotella corporis GAI 91000 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534675 | Antimicrobial activity against Fusobacterium varium ATCC 8501 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID529814 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 869 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524303 | Antibacterial activity against Pseudomonas aeruginosa P340 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529988 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 988 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534435 | Antimicrobial activity against Staphylococcus saccharolyticus ATCC 14953 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534907 | Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID533125 | Antimicrobial activity against Bacteroides distasonis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID433167 | Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534411 | Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524272 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534604 | Antimicrobial activity against Enterobacteriaceae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID535162 | Antimicrobial activity against Acinetobacter by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID433011 | Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523725 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E346 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523936 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530199 | Bactericidal activity against Pseudomonas aeruginosa assessed as log reduction in bacterial count at >=4 times MIC for 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534673 | Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523585 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID574470 | Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID530182 | AUC in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495736 | Kcat/Km ratio of Escherichia coli CMY-2 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID588130 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID523573 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534643 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID433351 | Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524289 | Antibacterial activity against Pseudomonas aeruginosa P373 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524118 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A894 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433354 | Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID495701 | Kcat/Km ratio of Escherichia coli TEM-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID433015 | Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID495713 | Kcat/Km ratio of Pseudomonas aeruginosa IMP-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556909 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529776 | Antibacterial activity against Pseudomonas aeruginosa isolate 1036 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495687 | Activity of Klebsiella pneumoniae SHV-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID351203 | Antimicrobial activity against Acinetobacter baumannii isolate producing metallo beta-lactamase by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Global challenge of multidrug-resistant Acinetobacter baumannii. |
| AID565918 | fT>MIC in Klebsiella pneumoniae isolate KPC 354 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID523952 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433154 | Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523545 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID518398 | T>MIC in bacilli infected patients with severe renal impairment at 250 mg administered as 4 hrs infusion every 12 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID534927 | Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID495668 | Antimicrobial activity against Escherichia coli OC 6697 expressing beta-lactamase CMY-2 and containing plasmid AmpC assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID564677 | fCmax in ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID533417 | Antimicrobial activity against Micromonas micros by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID523944 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433160 | Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556943 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID574467 | Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID573394 | Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534667 | Antimicrobial activity against Prevotella intermedia ATCC 25611 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495672 | Antimicrobial activity against Klebsiella pneumoniae OC 4094 expressing extended-spectrum Beta-lactamase TEM-26 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID518376 | Antimicrobial activity against Enterococcus sp. clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID574668 | Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID556950 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID565834 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 361 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID557175 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523909 | Antibacterial activity against Acinetobacter baumannii A849 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID565934 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 357 in immunocompromized mouse thigh infection model assessed as decrease in bacterial density in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID1318923 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 264-104354 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID556926 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524310 | Antibacterial activity against Pseudomonas aeruginosa P326 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535837 | Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID530003 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 979 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534680 | Antimicrobial activity against Capnocytophaga ochracea GAI 5586 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID518393 | Antimicrobial activity against Haemophilus influenzae clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID573795 | Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID524116 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A885 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534708 | Antimicrobial activity against Eubacterium limosum by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID574459 | Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID524309 | Antibacterial activity against Pseudomonas aeruginosa P376 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433360 | Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID547797 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237F mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID1318926 | Antibacterial activity against Pseudomonas aeruginosa PAO1 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID556921 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523759 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535370 | Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as intermediate isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523770 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523586 | Antibacterial activity against Pseudomonas aeruginosa P332 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564672 | fT>MIC in Pseudomonas aeruginosa selected at 8 ug/ml MIC infected ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID511705 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA8119 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID564451 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1036 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534472 | Antimicrobial activity against Bacteroides uniformis ATCC 8492 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID535143 | Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID580400 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as constipation at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID518396 | Antimicrobial activity against Enterobacteriaceae clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID433162 | Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523722 | Antibacterial activity against Acinetobacter baumannii A903 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID519796 | Inhibition of Bocillin FL binding to PBP1A in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID535835 | Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID556922 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529765 | Antibacterial activity against Pseudomonas aeruginosa isolate 1029 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID557151 | Antimicrobial activity against Pseudomonas aeruginosa 2062713 B-Q isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID586235 | Antimicrobial activity against Escherichia coli J53 | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID523914 | Antibacterial activity against Acinetobacter baumannii A908 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556714 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495722 | Activity of Pseudomonas aeruginosa AmpC relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID534696 | Antimicrobial activity against Porphyromonas uenonis by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523928 | Antibacterial activity against beta-lactamase-negative Escherichia coli E347 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534669 | Antimicrobial activity against Prevotella denticola GAI 5490 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID433164 | Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID425076 | Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID518379 | Antimicrobial activity against Staphylococcus aureus clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID530200 | Antibacterial activity against Pseudomonas aeruginosa at 2 times MIC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID535129 | Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573552 | Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523541 | Antibacterial activity against beta-lactamase-negative Escherichia coli E350 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534686 | Antimicrobial activity against Bacteroides uniformis by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID557172 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534684 | Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID564488 | fT>MIC in Pseudomonas aeruginosa selected at 4 ug/ml MIC infected human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID564675 | fCmax in ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID588125 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID534415 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID533384 | Antimicrobial activity against Bacteroides nordii assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524275 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556927 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433191 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID351202 | Antimicrobial activity against Acinetobacter baumannii isolate producing IMP-4 beta-lactamase by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Global challenge of multidrug-resistant Acinetobacter baumannii. |
| AID534920 | Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID564496 | fT>MIC in Pseudomonas aeruginosa selected at 32 ug/ml MIC infected ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID574043 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID432996 | Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID518367 | Antimicrobial activity against Proteus mirabilis clinical isolates | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID524427 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID523555 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433193 | Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534682 | Antimicrobial activity against Veillonella dispar ATCC 17748 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495688 | Activity of Escherichia coli CTX-M-15 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556487 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433014 | Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524297 | Antibacterial activity against Pseudomonas aeruginosa P337 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529993 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1029 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID564683 | Antimicrobial activity against Pseudomonas aeruginosa selected at MIC 2 to 8 ug/ml infected ICR mouse assessed as reduction in bacterial load at 1g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID533380 | Antimicrobial activity against Bacteroides merdae assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID556953 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433018 | Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID547761 | Antimicrobial activity against Klebsiella pneumoniae 1534 expressing beta-lactamase KPC-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID511699 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA5441 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID511707 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA8858 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID587023 | AUC (0 to 12 hrs) in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID524322 | Antibacterial activity against Acinetobacter baumannii A884 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534681 | Antimicrobial activity against Veillonella parvula ATCC 10790 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID564495 | fT>MIC in Pseudomonas aeruginosa selected at 16 ug/ml MIC infected ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID535127 | Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID530016 | Cmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495667 | Antimicrobial activity against wild type Klebsiella pneumoniae OC 15263 expressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID574463 | Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID587032 | AUC (0 to infinity) in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID529777 | Antibacterial activity against Pseudomonas aeruginosa isolate 1058 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID511710 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA641 parC P105T mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID556940 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524076 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P319 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534689 | Antimicrobial activity against Bacteroides stercoris by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID519799 | Inhibition of Bocillin FL binding to PBP3 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID495706 | Kcat/Km ratio of Escherichia coli CMY-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID433166 | Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556949 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID518395 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolate obtained from critically ill patients | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID433169 | Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID547765 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBR322-catI carrying beta-lactamase KPC-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID556932 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID547801 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237W mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID425083 | Antimicrobial activity against beta lactamase-positive Prevotella nigrescens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID564456 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534706 | Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID565830 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 359 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID564501 | fT>MIC in Pseudomonas aeruginosa selected at 32 ug/ml MIC infected human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID530188 | fT>MIC in neutropenic mouse thigh infection model at 4 to 8 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529816 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1055 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID580405 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as phlebitis at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID425334 | Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID530022 | AUC (0 to 24 hrs) in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425115 | Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID511712 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA1165 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID547785 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237L mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID523910 | Antibacterial activity against Acinetobacter baumannii A910 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523940 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523546 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID580410 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as hypokalemia at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID534899 | Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524079 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P327 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534668 | Antimicrobial activity against Prevotella melaninogenica JCM 6325 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID564682 | fAUC in human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID524315 | Antibacterial activity against Acinetobacter baumannii A851 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433365 | Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID425097 | Antimicrobial activity against Peptostreptococcus anaerobius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID523410 | Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 by broth macrodilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID565927 | fT>MIC in Klebsiella pneumoniae isolate KPC 361 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID524270 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495670 | Antimicrobial activity against Escherichia coli DH5-alpha expressing beta-lactamase TEM-1 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID425323 | Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID1318918 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID433180 | Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523601 | Antibacterial activity against Pseudomonas aeruginosa P353 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556750 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID574034 | Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID432993 | Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID495726 | Activity of Serratia marcescens SME-3 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID557163 | Antimicrobial activity against Escherichia coli 1780064 A-X isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524321 | Antibacterial activity against Acinetobacter baumannii A910 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556206 | T>MIC in Enterobacteriaceae-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524408 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID534463 | Antimicrobial activity against Bacteroides fragilis GAI 0558 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID574023 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID530183 | AUC in healthy human at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495709 | Kcat/Km ratio of Pseudomonas aeruginosa OXA-10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID533409 | Antimicrobial activity against Finegoldia magna by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID529779 | Antibacterial activity against Pseudomonas aeruginosa isolate 944 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523950 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433200 | Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID433006 | Antibacterial activity against Corynebacterium accolens isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524096 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A848 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535840 | Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID523724 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E345 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587047 | Toxicity in healthy human assessed as pancreatitis at 500 mg, iv after 2 days | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID588128 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID523737 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E446 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529964 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 988 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523587 | Antibacterial activity against Pseudomonas aeruginosa P356 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556958 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425107 | Antimicrobial activity against Clostridium sordellii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534427 | Antimicrobial activity against Anaerococcus prevotii ATCC 9321 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523591 | Antibacterial activity against Pseudomonas aeruginosa P319 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID565823 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 353 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID556211 | Drug excretion in pyelonephritis patient urine at 500 mg/kg, iv administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529796 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1052 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556517 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID511716 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA1378 harboring gyrA T83I mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID523898 | Antibacterial activity against Pseudomonas aeruginosa P376 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534622 | Antimicrobial activity against Non-ESBL Escherichia coli by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425096 | Antimicrobial activity against Micromonas micros isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID524428 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID565835 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 361 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID524422 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with urinary tract infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID587037 | Tmax in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID524110 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A908 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425087 | Antimicrobial activity against beta lactamase-positive Prevotella buccae isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID433163 | Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523554 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524267 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587026 | Volume of distribution at steady state in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID535137 | Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID546618 | Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID523758 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564679 | fCmax in human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID433368 | Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556930 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID573563 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID530011 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 936 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495708 | Kcat/Km ratio of Enterobacter cloacae AmpC | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID1296369 | Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as efficiency of acylation reaction by measuring ratio of K2 to Kapp by stopped-flow spectrofluorimetric method | 2016 | Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7 | Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC. |
| AID534663 | Antimicrobial activity against ESBL producing Proteus mirabilis by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523539 | Antibacterial activity against beta-lactamase-negative Escherichia coli E347 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495699 | Activity of Pseudomonas aeruginosa SPM-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID530186 | Antibacterial activity against Pseudomonas aeruginosa isolate assessed as log reduction in bacterial count at MIC after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433020 | Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID433156 | Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID580388 | Antibacterial activity against Escherichia coli isolated from patient with urinary tract infection receiving drug at 500 mg, iv administered every 8 hrs for 10 days measured after post drug therapy | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID519797 | Inhibition of Bocillin FL binding to PBP1B in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID557158 | Antimicrobial activity against Escherichia coli 1889647 B-H isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID574473 | Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID530024 | AUC (0 to 24 hrs) in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID587030 | Cmax in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID556470 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425333 | Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529773 | Antibacterial activity against Pseudomonas aeruginosa isolate 1082 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID351201 | Antimicrobial activity against Acinetobacter baumannii isolate producing OXA-23 beta-lactamase by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Global challenge of multidrug-resistant Acinetobacter baumannii. |
| AID557166 | Antimicrobial activity against Staphylococcus aureus 2215767-9 B-S isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534601 | Antimicrobial activity against Enterobacteriaceae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID530012 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 988 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433010 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523772 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495738 | Kcat/Km ratio of Enterobacter cloacae AmpC relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID573797 | Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID557169 | Antimicrobial activity against Staphylococcus epidermidis 2297262-9 B-V isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524090 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P363 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425110 | Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID556721 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1475190 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12 | Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC. |
| AID523411 | Antimicrobial activity against oprD-deficient Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 1 g administered at 4 hrs infusion regimen every 8 hrs by time-kill as | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID433012 | Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID530005 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1058 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529792 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1055 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529768 | Antibacterial activity against Pseudomonas aeruginosa isolate 1055 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523416 | Antimicrobial activity against oprD-deficient Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 500 mg administered at 1 hr infusion regimen every 8 hrs by time-kill | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID529769 | Antibacterial activity against Pseudomonas aeruginosa isolate 1062 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523560 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID574052 | Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID524103 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A912 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534679 | Antimicrobial activity against Desulfovibrio piger DSM 749 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573823 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID533369 | Antimicrobial activity against Bacteroides vulgatus by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534412 | Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID556479 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1373335 | Inhibition of recombinant human GABA A alpha2beta2gamma2 receptor expressed in CHO-K1 cells at 300 uM incubated at room temperature for 15 mins before the GABA addition fluorescence spectrometry | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID564487 | fT>MIC in Pseudomonas aeruginosa selected at 2 ug/ml MIC infected human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID565937 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 356 in immunocompetent mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 2 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID564467 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1080 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529967 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 968 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID574465 | Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID530020 | Tmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529969 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1029 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID511709 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA9087 harboring gyrA T83I mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID523919 | Antibacterial activity against Acinetobacter baumannii A890 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433364 | Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556952 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID580378 | Antibacterial activity against Escherichia coli infected in microbiologically evaluable patient with UTI assessed as cure rate at 500 mg, iv administered every 8 hrs for 10 days measured at test-of-cure visit | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID556956 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID530015 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 968 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID511715 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA1328 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID556230 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID556746 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID574004 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574033 | Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID519805 | Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID580401 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as diarrhea at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID573596 | Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID548004 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237P mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID524317 | Antibacterial activity against Acinetobacter baumannii A911 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433197 | Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524308 | Antibacterial activity against Pseudomonas aeruginosa P358 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID519816 | Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID530004 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1036 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID511702 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA6218 harboring gyrA D87N mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID433196 | Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID510503 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID523745 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E465 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID557156 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID587033 | Terminal half life in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID495673 | Antimicrobial activity against Klebsiella pneumoniae OC 5367 expressing beta-lactamase KPC-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523916 | Antibacterial activity against Acinetobacter baumannii A931 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534921 | Antimicrobial activity against Serratia marcescens assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523730 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E409 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530032 | Half-life in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425089 | Antimicrobial activity against Porphyromonas gingivalis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID574051 | Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID425332 | Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID524088 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P340 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524111 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A898 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID548020 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237E mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID530028 | Elimination rate constant in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 10 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529986 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 896 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1155049 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition after 20 hrs by microdilution method | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5 | Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. |
| AID523895 | Antibacterial activity against Pseudomonas aeruginosa P370 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524300 | Antibacterial activity against Pseudomonas aeruginosa P352 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534901 | Antimicrobial activity against Citrobacter assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523582 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523915 | Antibacterial activity against Acinetobacter baumannii A898 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529956 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1036 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573598 | Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID556223 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID530007 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 944 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID510506 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID524405 | Antibacterial activity against carbapenemase-producing Klebsiella pneumoniae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID530178 | Cmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524080 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P323 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556941 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433358 | Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID524280 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433201 | Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID535846 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID432997 | Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID535847 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID529965 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1006 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID519813 | Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID547781 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237I mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID565824 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 354 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID495717 | Activity of Klebsiella pneumoniae SHV-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523954 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524276 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529985 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1060 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523712 | Antibacterial activity against Pseudomonas aeruginosa P340 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433357 | Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556928 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1318924 | Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 91433 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID556243 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID510510 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID533638 | Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID433178 | Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID425109 | Antimicrobial activity against Clostridium cadaveris isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534677 | Antimicrobial activity against Bilophila wadsworthia WAL 7959 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556482 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433370 | Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID573565 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523762 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524323 | Antibacterial activity against Acinetobacter baumannii A896 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495692 | Activity of Pseudomonas aeruginosa AmpC | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID533428 | Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534455 | Antimicrobial activity against Lactobacillus casei subsp. casei JCM 1134 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524101 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A867 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534468 | Antimicrobial activity against Bacteroides vulgatus GAI 0673 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556227 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID557145 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID564466 | Antimicrobial activity against Pseudomonas aeruginosa isolate 821 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID519818 | Induction of morphological changes in Escherichia coli MC4100 assessed as induction of sphere formation at antimicrobial MIC after 4 hrs by microscopy | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID495735 | Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID564684 | Antimicrobial activity against Pseudomonas aeruginosa selected at MIC 2 to 16 ug/ml infected ICR mouse assessed as reduction in bacterial load at 2g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID495705 | Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556244 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523941 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523713 | Antibacterial activity against Acinetobacter baumannii A898 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529815 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 886 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID530001 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1082 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523544 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530030 | Elimination rate constant in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425088 | Antimicrobial activity against Porphyromonas asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID523932 | Antibacterial activity against beta-lactamase-negative Escherichia coli E409 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID519812 | Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID556468 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID519806 | Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID523561 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID580495 | Drug related treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as nausea at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID523740 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E456 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523749 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E358 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529794 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 935 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556506 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID533420 | Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID574003 | Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID519819 | Induction of morphological changes in Pseudomonas aeruginosa 27853 assessed as induction of sphere formation at antimicrobial MIC after 60 mins by microscopy | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID523743 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E451 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425326 | Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529812 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 993 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523948 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564462 | Antimicrobial activity against Pseudomonas aeruginosa isolate 913 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID557148 | Antimicrobial activity against Staphylococcus aureus 1889640 A-Z isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID556220 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID557144 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1207367 | Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform | |||
| AID530027 | Volume of distribution in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495745 | Kcat/Km ratio of Acinetobacter baumannii OXA-23 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID529996 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1055 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523924 | Antibacterial activity against Acinetobacter baumannii A903 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530176 | Clearance in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID510512 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-51 | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID495674 | Antimicrobial activity against wild type Klebsiella oxytoca OC 4076 expressing Beta-lactamase K1 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID495698 | Activity of Pseudomonas aeruginosa IMP-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID533134 | Antimicrobial activity against Bacteroides fragilis assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID580425 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as >=1 adverse event at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID565933 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 356 in immunocompromized mouse thigh infection model assessed as decrease in bacterial density in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID425325 | Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID433353 | Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID529981 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1058 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID530023 | AUC (0 to 24 hrs) in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529784 | Antibacterial activity against Pseudomonas aeruginosa isolate 988 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523742 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E459 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533372 | Antimicrobial activity against Bacteroides vulgatus assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID529788 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 993 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523542 | Antibacterial activity against beta-lactamase-negative Escherichia coli E408 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524306 | Antibacterial activity against Pseudomonas aeruginosa P370 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523921 | Antibacterial activity against Acinetobacter baumannii A891 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556503 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID510505 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID588123 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID574472 | Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID495702 | Kcat/Km ratio of Klebsiella pneumoniae SHV-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523564 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495747 | Inhibition of Pseudomonas aeruginosa AmpC assessed as inhibition of nitrocefin hydrolysis | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID524292 | Antibacterial activity against Pseudomonas aeruginosa P320 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID1649608 | Inhibition of Acinetobacter baumanni PBP3 assessed as reduction in fluorescence intensity of bocillin labeled protein by SDS-PAGE analysis | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. |
| AID523949 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534477 | Antimicrobial activity against Prevotella bivia ATCC 29303 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID529803 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 944 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523935 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556934 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523738 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E450 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523596 | Antibacterial activity against Pseudomonas aeruginosa P334 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID518397 | T>MIC in bacilli infected patients with moderate renal impairment at 250 mg administered as 1 hr infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. |
| AID556208 | T>MIC in methicillin-susceptible Staphylococcus aureus-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID573802 | Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID556735 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID564458 | Antimicrobial activity against Pseudomonas aeruginosa isolate 896 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID523719 | Antibacterial activity against Acinetobacter baumannii A891 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556942 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433371 | Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID564671 | fT>MIC in Pseudomonas aeruginosa selected at 4 ug/ml MIC infected ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529998 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 935 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID574460 | Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID556939 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID588131 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. |
| AID510514 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID534440 | Antimicrobial activity against Clostridium perfringens ATCC 13124 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID574667 | Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID529787 | Antibacterial activity against Pseudomonas aeruginosa isolate 968 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495693 | Activity of Enterobacter cloacae AmpC | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID495737 | Kcat/Km ratio of Pseudomonas aeruginosa AmpC relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID557150 | Antimicrobial activity against Pseudomonas aeruginosa 1821383 B-E isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523727 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E348 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534683 | Antimicrobial activity against Bacteroides fragilis by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523715 | Antibacterial activity against Acinetobacter baumannii A897 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523418 | Antibacterial activity against beta-lactamase-negative Escherichia coli E345 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523588 | Antibacterial activity against Pseudomonas aeruginosa P369 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534465 | Antimicrobial activity against Bacteroides fragilis GAI 10150 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID565831 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 359 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID530013 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1006 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1207555 | Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform | |||
| AID557176 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433194 | Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523566 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495733 | Kcat/Km ratio of Escherichia coli CTX-M-15 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523563 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535845 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID425112 | Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID530184 | AUC in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID574666 | Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID519814 | Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID534448 | Antimicrobial activity against Bifidobacterium longum subsp. longum ATCC 15707 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523765 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523946 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587040 | AUC (0 to infinity) in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID534670 | Antimicrobial activity against Prevotella oralis ATCC 33269 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524073 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P369 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID573836 | Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID580386 | Antibacterial activity against Proteus mirabilis infected in microbiologically evaluable patient with UTI assessed as cure rate at 500 mg, iv administered every 8 hrs for 10 days measured at test-of-cure visit | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID524291 | Antibacterial activity against Pseudomonas aeruginosa P319 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556955 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534460 | Antimicrobial activity against Bacteroides fragilis GAI 5562 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556948 | Antimicrobial activity against Enterococcus faecalis 1780065 B-B isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534461 | Antimicrobial activity against Bacteroides fragilis ATCC 25285 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523753 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E361 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529963 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 936 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID519800 | Inhibition of Bocillin FL binding to PBP4 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID433192 | Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523593 | Antibacterial activity against Pseudomonas aeruginosa P322 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495714 | Kcat/Km ratio of Pseudomonas aeruginosa SPM-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID533130 | Antimicrobial activity against Bacteroides distasonis assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID558427 | Antimicrobial activity against Escherichia coli ATCC 25922 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activity of doripenem against Burkholderia pseudomallei. |
| AID556702 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523951 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID565916 | fT>MIC in Klebsiella pneumoniae isolate KPC 353 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID573601 | Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID565829 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 357 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID1318919 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID523953 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523955 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529790 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 869 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID524307 | Antibacterial activity against Pseudomonas aeruginosa P341 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID573799 | Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523565 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529798 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 906 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523557 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529802 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 931 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID533392 | Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID557157 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID530177 | Clearance in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 150 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524420 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID565833 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 360 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID533404 | Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID556209 | T>MIC in penicillin-susceptible Streptococcus pneumoniae-infected patient at 250 to 1000 mg/kg, at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529775 | Antibacterial activity against Pseudomonas aeruginosa isolate 979 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556221 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523595 | Antibacterial activity against Pseudomonas aeruginosa P323 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523773 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P332 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523558 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534434 | Antimicrobial activity against Gemella morbillorum ATCC 27824 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID495676 | Antimicrobial activity against wild type Serratia marcescens OC 7554 expressing beta-lactamase SME-3 and containing Carbapenemase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID548036 | Antimicrobial activity against Escherichia coli DH10B by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID523947 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523760 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523407 | Antimicrobial activity against oprD-deficient Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 1 g administered at 4 hrs infusion regimen by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID530009 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1060 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573583 | Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID1155048 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa SR27156 assessed as growth inhibition after 20 hrs by microdilution method | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5 | Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. |
| AID511706 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA8721 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID574469 | Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID523896 | Antibacterial activity against Pseudomonas aeruginosa P341 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534438 | Antimicrobial activity against Clostridium clostridioforme NCTC 11224 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID425318 | Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID529975 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1005 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524113 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A897 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529978 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 906 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556938 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523744 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E460 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523597 | Antibacterial activity against Pseudomonas aeruginosa P337 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524093 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P358 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587028 | Non-renal clearance in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID495710 | Kcat/Km ratio of Klebsiella pneumoniae KPC-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID534624 | Antimicrobial activity against Escherichia coli assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425121 | Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID523771 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524302 | Antibacterial activity against Pseudomonas aeruginosa P365 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564489 | fT>MIC in Pseudomonas aeruginosa selected at 8 ug/ml MIC infected human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID556200 | T>MIC in Prevotella spp.-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1296368 | Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as second order rate constant for acylenzyme formation by stopped-flow spectrofluorimetric method | 2016 | Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7 | Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC. |
| AID529968 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 993 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425117 | Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID524095 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P326 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523938 | Antibacterial activity against beta-lactamase-negative Escherichia coli E425 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534457 | Antimicrobial activity against Lactobacillus plantarum JCM 1149 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573798 | Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID524098 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A864 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524293 | Antibacterial activity against Pseudomonas aeruginosa P322 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495744 | Kcat/Km ratio of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523556 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523415 | Antimicrobial activity against oprD-deficient Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 1 g administered at 1 hr infusion regimen every 8 hrs by time-kill ass | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID425111 | Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID511701 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA5600 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID523746 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E483 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529987 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 936 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID519817 | Antimicrobial activity against Pseudomonas aeruginosa 27853 by CLSI protocol based broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID523547 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530026 | Volume of distribution in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529774 | Antibacterial activity against Pseudomonas aeruginosa isolate 906 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523893 | Antibacterial activity against Pseudomonas aeruginosa P349 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425319 | Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID510504 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID523570 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524107 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A884 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556203 | T>MIC in Bacteroides spp.-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523901 | Antibacterial activity against Acinetobacter baumannii A850 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523934 | Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523717 | Antibacterial activity against Acinetobacter baumannii A890 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID548000 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237N mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID565828 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 357 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID565922 | fT>MIC in Klebsiella pneumoniae isolate KPC 357 infected in human at 2 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID523550 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523413 | Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 500 mg administered at 4 hrs infusion regimen every 8 hrs by time-kill assa | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID529771 | Antibacterial activity against Pseudomonas aeruginosa isolate 1005 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529991 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 968 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523589 | Antibacterial activity against Pseudomonas aeruginosa P373 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID511703 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA7461 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID534650 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID580389 | Antibacterial activity against Serratia marcescens isolated from patient with urinary tract infection receiving drug at 500 mg, iv administered every 8 hrs for 10 days measured after post drug therapy | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID529804 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1050 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID519804 | Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID523590 | Antibacterial activity against Pseudomonas aeruginosa P335 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530014 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 927 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524304 | Antibacterial activity against Pseudomonas aeruginosa P349 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529966 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 927 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534474 | Antimicrobial activity against Bacteroides ureolyticus NCTC 10941 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556495 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID573796 | Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID556945 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523751 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E360 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529955 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 979 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID425324 | Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID556957 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID556245 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 20 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID580411 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as abdominal pain at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID565826 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 356 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID556498 | Antimicrobial activity against Escherichia coli 2297257 B-W isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID425116 | Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID580380 | Antibacterial activity against levofloxacin-resistant Escherichia coli infected in microbiologically evaluable patient with UTI assessed as cure rate at 500 mg, iv administered every 8 hrs for 10 days measured at test-of-cure visit | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID495684 | Antimicrobial activity against wild type Acinetobacter baumannii OC 16708 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID564498 | fT>MIC in Pseudomonas aeruginosa selected at 4 ug/ml MIC infected human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID523714 | Antibacterial activity against Acinetobacter baumannii A931 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556490 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495690 | Activity of Klebsiella pneumoniae Beta-lactamase TEM-26 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID587029 | Tmax in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID573835 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID565825 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 354 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID556513 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433352 | Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID529810 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 927 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433195 | Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID565931 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 353 in immunocompromized mouse thigh infection model assessed as decrease in bacterial density in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID580409 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as back pain at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID523723 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E344 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529789 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1029 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID564492 | fT>MIC in Pseudomonas aeruginosa selected at 2 ug/ml MIC infected ICR mouse at 1 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529808 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 988 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1155046 | Antibacterial activity against Pseudomonas aeruginosa YY165 deltamexB mutant assessed as growth inhibition after 20 hrs by microdilution method | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5 | Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. |
| AID510507 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID1296371 | Activity at Mycobacterium tuberculosis beta lactamase BlaC expressed in Escherichia coli assessed as ratio of Kcat to Km by spectrophotometric method | 2016 | Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7 | Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC. |
| AID535171 | Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID565939 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 356 in immunocompetent mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID524295 | Antibacterial activity against Pseudomonas aeruginosa P323 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523408 | Antimicrobial activity against oprD-deficient Pseudomonas aeruginosa PAO1 by broth macrodilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID556935 | Antimicrobial activity against Pseudomonas aeruginosa 1134642 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID573599 | Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID556494 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID495900 | Activity of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID556947 | Antimicrobial activity against Escherichia coli 1949821 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433198 | Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523927 | Antibacterial activity against beta-lactamase-negative Escherichia coli E346 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495719 | Activity of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID425327 | Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID565917 | fT>MIC in Klebsiella pneumoniae isolate KPC 354 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID495695 | Activity of Klebsiella pneumoniae KPC-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523592 | Antibacterial activity against Pseudomonas aeruginosa P320 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524294 | Antibacterial activity against Pseudomonas aeruginosa P327 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425119 | Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID562755 | Activity of Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID529785 | Antibacterial activity against Pseudomonas aeruginosa isolate 1006 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID535833 | Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID524087 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P365 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID425114 | Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID565935 | Bacteriostatic activity against Klebsiella pneumoniae isolate KPC 359 in immunocompromized mouse thigh infection model at 2 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID556944 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524298 | Antibacterial activity against Pseudomonas aeruginosa P338 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587044 | Renal clearance in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID564453 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1050 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534475 | Antimicrobial activity against Campylobacter gracilis JCM 8538 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID573819 | Antibacterial activity against Veillonella parvula by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523900 | Antibacterial activity against Acinetobacter baumannii A848 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID533400 | Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524288 | Antibacterial activity against Pseudomonas aeruginosa P369 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID1373334 | Toxicity in CD1 mouse assessed as induction of convulsion at 100 mg/kg, icv measured 1 hr after post dose | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529992 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 993 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534647 | Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523731 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E458 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID580382 | Antibacterial activity against levofloxacin-resistant Escherichia coli infected in clinically evaluable patient with UTI assessed as cure rate at 500 mg, iv administered every 8 hrs for 10 days measured at test-of-cure visit | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID495689 | Activity of Klebsiella oxytoca Beta-lactamase K1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID533385 | Antimicrobial activity against Clostridium difficile by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID524271 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587036 | Non-renal clearance in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID524085 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P352 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID548024 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237H mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID524102 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A911 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556914 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529994 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 869 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID533416 | Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID535843 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID580377 | Antibacterial activity against Staphylococcus aureus | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID495742 | Kcat/Km ratio of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID433199 | Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523734 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E437 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524314 | Antibacterial activity against Acinetobacter baumannii A865 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID564502 | fT>MIC in Pseudomonas aeruginosa selected at 2 ug/ml MIC infected ICR mouse at 2 g, sc administered 2 hrs post infection every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID573582 | Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529960 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1050 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID533376 | Antimicrobial activity against Bacteroides eggerthii assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID529997 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1062 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523763 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495685 | Antimicrobial activity against Acinetobacter baumannii OC 11738 expressing beta-lactamase OXA-23 and containing Carbapenemase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523553 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523584 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524432 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID557174 | Antimicrobial activity against Staphylococcus aureus 1134684 isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529970 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 869 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID574468 | Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID523732 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E412 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529795 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1005 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID548012 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237S mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID524100 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A851 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523942 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534887 | Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID564680 | fAUC in human at 1 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID524319 | Antibacterial activity against Acinetobacter baumannii A892 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556725 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID433373 | Antibacterial activity against Escherichia coli ATCC 25922 after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID523580 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID573573 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID580489 | Drug related treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as headache at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID529770 | Antibacterial activity against Pseudomonas aeruginosa isolate 935 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529786 | Antibacterial activity against Pseudomonas aeruginosa isolate 927 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534436 | Antimicrobial activity against Streptococcus constellatus ATCC 27923 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523594 | Antibacterial activity against Pseudomonas aeruginosa P327 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID433355 | Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID574026 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523741 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E430 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495732 | Kcat/Km ratio of Klebsiella pneumoniae SHV-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID573574 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID558424 | Selectivity ratio of MIC for Burkholderia pseudomallei by agar dilution method to MIC for Burkholderia pseudomallei by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activity of doripenem against Burkholderia pseudomallei. |
| AID534462 | Antimicrobial activity against Bacteroides fragilis NCTC 10581 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID564464 | Antimicrobial activity against Pseudomonas aeruginosa isolate 968 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529974 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 935 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433174 | Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID495711 | Kcat/Km ratio of Serratia marcescens SME-3 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID495734 | Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID534459 | Antimicrobial activity against Lactobacillus salivarius subsp. salivarius JCM 1231 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID556201 | T>MIC in Clostridium spp.-infected patient at 250 to 1000 mg/kg administered every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1318921 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 260-97103 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID524312 | Antibacterial activity against Acinetobacter baumannii A850 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556511 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534443 | Antimicrobial activity against Clostridium ramosum ATCC 25582 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID425330 | Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID519798 | Inhibition of Bocillin FL binding to PBP2 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID524412 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with complicated urinary tract infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID519807 | Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID524419 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID495694 | Activity of Pseudomonas aeruginosa OXA-10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523412 | Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 in hollow fiber system based pharmacokinetic-pharmacodynamic model assessed as reduction in bacterial count at 1 g administered at 4 hrs infusion regimen every 8 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. |
| AID556719 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID556946 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534431 | Antimicrobial activity against Peptoniphilus asaccharolyticus WAL 3218 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID587038 | Cmax in healthy human at 500 mg, iv | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID530017 | Cmax in Pseudomonas aeruginosa ATCC 27853 infected neutropenic ICR mouse at 50 mg/kg, sc administered as single dose 2 hrs postinfection by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534432 | Antimicrobial activity against Peptoniphilus indolicus GAI 0915 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524115 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A890 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID530008 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1050 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524278 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556744 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529999 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1005 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID433176 | Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID534466 | Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30079 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID529976 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1052 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556489 | Antimicrobial activity against Escherichia coli 1949825 B-K isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524415 | Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID425317 | Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. |
| AID534904 | Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID556515 | Antimicrobial activity against Escherichia coli 1889645 B-I isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523939 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556726 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID573551 | Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534881 | Antimicrobial activity against Enterobacter cloacae assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524285 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529817 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1062 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556214 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID580375 | Antibacterial activity against Enterococcus faecalis | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID564681 | fCmax in human at 2 g, iv administered as 4 hrs infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID558426 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activity of doripenem against Burkholderia pseudomallei. |
| AID511714 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA1327 harboring gyrA T83I and parC S87L mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID534664 | Antimicrobial activity against Proteus mirabilis assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID565925 | fT>MIC in Klebsiella pneumoniae isolate KPC 360 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID535168 | Antimicrobial activity against imipenem susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524089 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P349 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID511704 | Antimicrobial activity against MexB overexpressing Pseudomonas aeruginosa isolate PA8108 harboring gyrA T83I mutant gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. |
| AID523899 | Antibacterial activity against Pseudomonas aeruginosa P326 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524410 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with urinary tract infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID534676 | Antimicrobial activity against Fusobacterium necrophorum ATCC 25286 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID529813 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1029 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495720 | Activity of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID557173 | Antimicrobial activity against Escherichia coli 1949820 B-N isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID565930 | Antimicrobial activity against Klebsiella pneumoniae isolate KPC 361 in immunocompromized mouse thigh infection model assessed as reduction in bacterial load in mouse thigh at 1 g after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID523728 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E350 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524268 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556512 | Antimicrobial activity against Escherichia coli 1949826 B-L isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID573558 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID433372 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID535834 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID547773 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237A mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID530191 | Antibacterial activity against Pseudomonas aeruginosa isolate 1060 assessed as log reduction in bacterial count at 4 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID523579 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534454 | Antimicrobial activity against Lactobacillus brevis subsp. brevis JCM 1059 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524097 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A850 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523548 | Antibacterial activity against beta-lactamase-negative Escherichia coli E424 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID548032 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237R mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID556738 | Antimicrobial activity against Enterococcus faecalis 2215770 B-T isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID574005 | Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523756 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534429 | Antimicrobial activity against Finegoldia magna ATCC 29328 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID548008 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Q mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID529995 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 886 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID524114 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A929 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529783 | Antibacterial activity against Pseudomonas aeruginosa isolate 936 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556920 | Antimicrobial activity against Escherichia coli 1135121 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529801 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1058 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID534450 | Antimicrobial activity against Eggerthella lenta ATCC 25559 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID534447 | Antimicrobial activity against Bifidobacterium breve ATCC 15700 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524423 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with urinary tract infection assessed as cure rate at test-of-cure visit by mMITT analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID573595 | Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523567 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523923 | Antibacterial activity against Acinetobacter baumannii A901 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535134 | Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID524108 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A896 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529957 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1058 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495712 | Kcat/Km ratio of Pseudomonas aeruginosa VIM-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523908 | Antibacterial activity against Acinetobacter baumannii A892 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID534671 | Antimicrobial activity against Prevotella oris ATCC 33573 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID557161 | Antimicrobial activity against Escherichia coli 1821385 B-C isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523575 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID556235 | Antimicrobial activity against Staphylococcus haemolyticus 1949819 B-M isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID523574 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID495724 | Activity of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID433175 | Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID556703 | Antimicrobial activity against Escherichia coli 1780063 B-A isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534678 | Antimicrobial activity against Desulfovibrio desulfuricans ATCC 29577 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID433362 | Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID529797 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1082 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID529778 | Antibacterial activity against Pseudomonas aeruginosa isolate 931 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID556219 | Antimicrobial activity against Escherichia coli 2062717 B-P isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID529809 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1006 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID573594 | Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534453 | Antimicrobial activity against Lactobacillus acidophilus JCM 1132 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523543 | Antibacterial activity against beta-lactamase-negative Escherichia coli E409 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID557159 | Antimicrobial activity against Escherichia coli 1821386 B-D isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1318922 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 262-101856 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID564468 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1093 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID433172 | Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. |
| AID557178 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 isolated from patient with pyelonephritis by Etest | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID534439 | Antimicrobial activity against Clostridium difficile GAI 10029 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID524283 | Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID524281 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529806 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 896 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495679 | Antimicrobial activity against Pseudomonas aeruginosa OC 4352 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID524273 | Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523761 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID510508 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID556936 | Antimicrobial activity against Proteus mirabilis 1134841 isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 16 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID556747 | Antimicrobial activity against Escherichia coli 1889646 B-F isolated from patient with pyelonephritis assessed as >3-log reduction in urinary bacterial titer after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. |
| AID524286 | Antibacterial activity against Pseudomonas aeruginosa P332 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID529805 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 1060 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID1207461 | Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform | |||
| AID523748 | Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E357 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID587046 | Toxicity in healthy human assessed as pancreatitis at 500 mg, iv after 1 day | 2011 | Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3 | Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. |
| AID1155047 | Antibacterial activity against Pseudomonas aeruginosa ATCC 25619 assessed as growth inhibition after 20 hrs by microdilution method | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5 | Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa. |
| AID534924 | Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID495681 | Antimicrobial activity against Pseudomonas aeruginosa OC 7052 expressing beta-lactamase VIM-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID529962 | fT>MIC in human infected with Pseudomonas aeruginosa isolate 896 at 500 mg administered as 4 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID495725 | Activity of Klebsiella pneumoniae KPC-2 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID495716 | Activity of Escherichia coli TEM-1 relative to Cephaloridine | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. |
| AID523911 | Antibacterial activity against Acinetobacter baumannii A884 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID1207427 | Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform | |||
| AID565921 | fT>MIC in Klebsiella pneumoniae isolate KPC 357 infected in human at 1 g administered as 4 hrs infusion every 8 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. |
| AID534467 | Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30144 by agar dilution method in presence of 5% laked sheep blood | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. |
| AID523562 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID573600 | Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID524413 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with complicated urinary tract infection assessed as cure rate at test-of-cure visit | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID523933 | Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 assessed as mutant prevention concentration after overnight incubation | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID523581 | Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 incubated up to 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Mutant prevention concentrations of four carbapenems against gram-negative rods. |
| AID535848 | Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID573800 | Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529972 | fT>MIC in neutropenic mouse infected with Pseudomonas aeruginosa isolate 1055 at 500 mg administered as 1 hr infusion | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. |
| AID580399 | Treatment emergent adverse event in intent-to-treat patient with complicated urinary tract infection assessed as headache at 500 mg/kg, iv administered every 8 hrs for 10 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.02) | 18.2507 |
| 2000's | 107 (27.37) | 29.6817 |
| 2010's | 244 (62.40) | 24.3611 |
| 2020's | 36 (9.21) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (59.06) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 33 (8.17%) | 5.53% |
| Reviews | 44 (10.89%) | 6.00% |
| Case Studies | 21 (5.20%) | 4.05% |
| Observational | 4 (0.99%) | 0.25% |
| Other | 302 (74.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age [NCT01381848] | Phase 1 | 52 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age [NCT01366651] | Phase 1 | 1 participants (Actual) | Interventional | 2012-03-31 | Terminated(stopped due to Trial terminated early per business decision.) | ||
| Multi-center, Open-label Randomized Controlled Trial on the Efficacy of Combination Antibiotic Therapy for Serious Infections Caused by Extensively Drug-resistant Gram-negative Bacteria (XDR-GNB) [NCT02134106] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-01-31 | Withdrawn(stopped due to The target cannot be achieved within timeline due to delay of ethics approval) | ||
| A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection [NCT01281462] | Phase 2 | 217 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers - a Pilot Study [NCT01311141] | Phase 4 | 6 participants (Anticipated) | Interventional | 2010-08-31 | Completed | ||
| Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients With Sepsis at Grady Health System [NCT01027897] | Phase 4 | 30 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01595438] | Phase 3 | 598 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator Associated Pneumonia [NCT00515034] | Phase 2 | 146 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections [NCT01110408] | Phase 3 | 41 participants (Actual) | Interventional | 2010-12-31 | Terminated(stopped due to Trial terminated early per business decision) | ||
| Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects [NCT00925392] | Phase 1 | 40 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Multicenter, Randomized, Open-Label, Phase 3 Study of Doripenem Versus a Comparator Antibiotic in the Treatment of Ventilator-Associated Pneumonia [NCT00211016] | Phase 3 | 318 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Versus Comparator Antibiotic in the Treatment of Complicated Intra-Abdominal Infections [NCT00210938] | Phase 3 | 478 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections [NCT01110382] | Phase 3 | 41 participants (Actual) | Interventional | 2010-12-31 | Terminated(stopped due to Trial terminated early per business decision) | ||
| A Phase 2 Study of Doripenem In The Treatment of Nosocomial and Ventilator-Associated Pneumonia In Hospitals [NCT00502801] | Phase 2 | 185 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections [NCT00965848] | Phase 4 | 270 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia [NCT00589693] | Phase 3 | 274 participants (Actual) | Interventional | 2008-04-30 | Terminated(stopped due to Observed lower cure rates and higher mortality rates in one of the treatment groups.) | ||
| A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis [NCT00210990] | Phase 3 | 403 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Versus Comparator Antibiotic in the Treatment of Complicated Intra-Abdominal Infections [NCT00229060] | Phase 3 | 483 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients [NCT01517815] | 50 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| A Multicenter, Randomized, Open-Label, Phase 3 Study to Compare the Safety and Effectiveness of Doripenem Versus a Comparator Antibiotic in Hospital-Acquired Pneumonia [NCT00211003] | Phase 3 | 240 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia [NCT01467648] | Phase 4 | 12 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region [NCT00986102] | Phase 4 | 216 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia [NCT01110421] | Phase 3 | 7 participants (Actual) | Interventional | 2010-12-31 | Terminated(stopped due to Trial terminated early per business decision) | ||
| Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection [NCT01401010] | Phase 4 | 12 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01599806] | Phase 3 | 641 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||